LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Gesloten

SectorGezondheidszorg

0.73 -3.95

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.72

Max

0.76

Belangrijke statistieken

By Trading Economics

Inkomsten

1.1M

-1.2M

Verkoop

141K

21M

Winstmarge

-5.978

Werknemers

330

EBITDA

1M

1.2M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+163.16% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

8.2M

34M

Vorige openingsprijs

4.68

Vorige sluitingsprijs

0.73

Nieuwssentiment

By Acuity

26%

74%

84 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Harvard Bioscience Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2025, 22:02 UTC

Winsten

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec 2025, 21:46 UTC

Winsten

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec 2025, 23:52 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec 2025, 23:36 UTC

Marktinformatie

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec 2025, 23:20 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec 2025, 23:15 UTC

Winsten

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec 2025, 22:59 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec 2025, 22:45 UTC

Marktinformatie

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec 2025, 22:40 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 22:06 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 22:02 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:00 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec 2025, 21:53 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec 2025, 21:50 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

10 dec 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 21:33 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec 2025, 21:32 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec 2025, 21:25 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec 2025, 21:16 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec 2025, 21:15 UTC

Winsten

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Vergelijking

Prijswijziging

Harvard Bioscience Inc Prognose

Koersdoel

By TipRanks

163.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD  163.16%

Hoogste 2 USD

Laagste 2 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harvard Bioscience Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.3 / 0.3401Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

84 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat